TWST — Twist Bioscience Corporation

Earnings Call Summary for Twist Bioscience (Q4 2025)

1. Key Financial Results and Metrics:

• Q4 Revenue: $99 million, up 17% year-over-year; exceeded guidance.
• Full Year Revenue: $376.6 million, a growth of 20% compared to fiscal 2024.
• Gross Margin: 51.3% for Q4 and 50.7% for the full year, significantly improved from 42.6% in fiscal 2024.
• Adjusted EBITDA: Loss of $7.8 million for Q4, improved by $9.2 million year-over-year; full year loss of $46.9 million, an improvement of $46.6 million from fiscal 2024.
• Cash Position: Ended fiscal 2025 with approximately $232.4 million in cash and investments.

2. Strategic Updates and Business Highlights:

• Synbio Revenue: $39.5 million in Q4, up 17% year-over-year; driven by the Express portfolio and AI-enabled drug discovery initiatives.
• NGS Revenue: $53 million in Q4, a 16% increase year-over-year; strong performance from diagnostic customers.
• Biopharma Services Revenue: $6.4 million in Q4, up 22% year-over-year; significant orders driven by AI discovery projects.
• Product Development: Introduction of the MRD Xpress solution expected in early 2026, aimed at cancer diagnostics with rapid turnaround times.
• Sales Organization Alignment: Enhanced collaboration between Synbio and Biopharma to leverage synergies and improve customer service.

3. Forward Guidance and Outlook:

• Fiscal 2026 Revenue Guidance: Expected between $425 million and $435 million, reflecting growth of approximately 13% to 15.5% year-over-year.
• DNA Synthesis and Protein Solutions Revenue: Expected between $194 million and $199 million, growth of 15% to 18%.
• NGS Applications Revenue: Expected between $231 million and $236 million, growth of 11% to 13.5%.
• Gross Margin Expectation: Anticipated to be above 52% for fiscal 2026, with a goal of achieving adjusted EBITDA breakeven by Q4 2026.

4. Bad News, Challenges, or Points of Concern:

• Customer Transition Impact: A significant customer transitioning from research to commercial has created a temporary revenue air pocket, affecting Q1 guidance.
• Market Penetration Concerns: Questions regarding the definition of market opportunities and revenue per assay, indicating potential investor uncertainty.
• Pricing Strategy: Ongoing promotions for academic customers could impact future pricing strategies and margins.

5. Notable Q&A Insights:

• Gross Margin Expectations: Incremental margins are expected to be lower due to tough comparisons from previous quarters; customer mix will influence margins.
• NGS Growth Drivers: Anticipated growth in NGS is contingent on the ramp-up of a key customer and new product introductions, with expectations of returning to 20% growth by Q4 2026.
• MRD Product Interest: High sensitivity and rapid turnaround times for MRD assays are expected to drive significant interest and growth, although current revenue contribution is small.
• Market Size and Penetration: Management acknowledged the need for clearer communication on market size and penetration to bolster investor confidence.

Overall, Twist Bioscience reported strong financial results and strategic advancements while facing some near-term challenges related to customer transitions and market clarity. The company remains optimistic about future growth driven by innovative product offerings and a focus on customer needs.